4314-66-3Relevant articles and documents
Water soluble complexes of the antiviral drugs, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine and acyclovir: The role of hydrophobicity in complex formation
Kenley,Jackson,Winterle,Shunko,Visor
, p. 648 - 653 (1986)
We investigated water-soluble complexes of various ligands with the antiviral drugs, 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) and 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (DHPG). For comparison, we also examined the 'parent' compounds, guanine and guanosine, as substrates for complex formation. Using the phase-solubility technique, we measured formation constant (K1) values at 23° C in pH 7 buffer. For a single substrate, formation constants with different ligands varied in the order: caffeine > pyridoxine ~~ cytidine > nicotinamide > sucrose. With caffeine as the ligand, formation constants with different substrates varied in the order: guanine > guanosine ~~ acyclovir > DHPG. The largest formation constant observed was 58 M-1 (for guanine-caffeine), and the smallest formation constant was 0.29 M-1 (for DHPG-sucrose). Examining the literature for formation constant data on compounds related to DHPB, and comparing literature data with our own, reveals a significant correlation between formation constants and ligand hydrophobicity. For 41 substrate-ligand pairs, least squares linear regression analysis of log K1 values versus various parameters reflecting donor-acceptor abilities (e.g., substrate and ligand HOMO and LUMO values, or substrate oxidation potentials) failed to significantly correlate. We conclude that ligand hydrophobicity is a general determinant of water soluble complex formation formation, but not necessarily the exclusive or dominant controlling factor for all complexes. Charge-transfer interactions are not important determinants of complex formation for the substrate-ligand combinations that we have considered.
Reactivity of biologically important reduced pyridines. 4. Effect of substitution on ferricyanide-mediated oxidation rates of various 1,4-dihydropyridines
Brewster,Simay,Czako,Winwood,Farag,Bodor
, p. 3721 - 3726 (2007/10/02)
-